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Abstract: In recent years, there have been significant advances in
the management of patients with lung cancer. This progress is
associated with increased use of medical intensive care units (ICUs)
for the management of a variety of complications related to cancer,
its treatment, or comorbid illnesses. At the same time, there are
advances in the care of critically ill patients in general. Over the last
decade, there are several studies that report progressive improve-
ment in the outcome of lung cancer patients admitted to the medical
ICUs. On average, the ICU and hospital mortality rates of lung
cancer patients are 36% and 51%, respectively. These rates are
approaching those of critically ill general population. However, it is
clear that not all lung cancer patients will benefit from this aggres-
sive care. Although there are no absolute predictors, the current
evidence suggests that advanced refractory cancer, poor baseline
performance status, the need for mechanical ventilation, and multi-
ple organ system failures are factors associated with worse ICU
outcome. Further studies are needed to better triage patients who are
going to benefit from ICU care; determine the optimal duration of
this care; and assess the impact of this therapy on the long-term
survival, cancer treatment, and quality of life of these patients.
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Lung cancer—the third most common malignancy in thehuman body—remains the leading cause of cancer mor-
tality in both men and women around the world. In the United
States, death by lung cancer accounts for 29% of all cancer-
induced deaths in males and 26% in females.1 Largely due to
improvement in surgical techniques and combined therapies,
the 1-year relative survival rate for lung cancer has increased
from 35% in the period 1975–1979 to 41% in 2001–2004.
However, the 5-year survival rate for all stages combined is
only 15%.1–3
Patients with lung cancer, regardless of type or stage,
commonly require intensive care unit (ICU) services for a
variety of acute illnesses related to the underlying malig-
nancy, treatment, or comorbid conditions. It is the most
common solid tumor to require ICU admission; the disease
accounts for 16% of all cancer-related admissions to the
ICU.4,5 A recent report linking Surveillance, Epidemiology,
and End Results and Medicare databases for elderly patients
with stages IIIB and IV lung cancer revealed an annual
increase of 6.6% in ICU use with significantly higher health
care cost.6 Given the poor overall prognosis associated with
lung cancer, there is controversy about the value of ICU care
provided to this patient population. The issue that is not
resolved by the larger database studies, however, is how
many lung cancer patients have expected short-term ICU
stays (e.g., arrhythmia), and how many have catastrophic
illnesses that are associated with multiple organ system fail-
ure. Prohibition or significant limitation of intensive care
services is unlikely to be morally or politically feasible.
Therefore, this review outlines the main indications for med-
ical ICU care for lung cancer patients—specifically those who
develop critical illnesses associated with their malignancy—
and discusses recent data on their outcome as well as predic-
tors from which lung cancer patients are likely to benefit.
This review focuses on the medical ICU needs of the lung
cancer patient and does not address the ICU needs after lung
resection surgery.
INDICATIONS FOR MEDICAL ICU ADMISSION
In general, lung cancer patients are admitted to the
medical ICU for diagnoses that are similar to those of other
patients. According to a study of critically ill lung cancer
patients by Adam and Soubani,7 the main causes for admis-
sion to the medical ICU are acute respiratory failure (49%),
cardiovascular problems (25%), sepsis (8%), and neurologic
impairment (5%). Other reasons for admission include renal
and metabolic abnormalities and bleeding disorders. The
indications for admission to the medical ICU for lung cancer
patients may be classified as cancer-related complications,
treatment-related complications, and comorbid illnesses.
These indications are summarized in Table 1.
Cancer-Related Complications
Because lung cancer arises in the bronchial tree and
pulmonary parenchyma, it is often associated with complica-
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tions involving other thoracic organs. Lung cancer may
invade the superior vena cava causing superior vena cava
syndrome or directly compress the trachea. In both instances,
the diagnosis is usually made in a timely fashion so that
ambulatory therapy can be administered, but when ICU care
is required, these patients are critically ill with disease pro-
cesses that are proceeding rapidly. Airway obstruction and
concomitant postobstructive pneumonia, as well as malignant
pleural effusions, are common in lung cancer and can lead to
acute pulmonary decompensation in patients with marginally
controlled chronic obstructive pulmonary disease. Massive
hemoptysis is either promptly fatal or manageable by several
different bronchoscopic procedures, but these patients can be
quite unstable. Most cases of pulmonary embolism secondary
to hypercoagulable state related to the underlying malignancy
are either asymptomatic or difficult to distinguish from the
other causes of increased dyspnea in these patients but can
cause severe respiratory distress. Electrolytes abnormali-
ties—hypercalcemia, hyponatremia, and hypokalemic alka-
losis—are not uncommon in these patients and may, on
occasion, require ICU care. Most of the complications of
metastases to the neuraxis (e.g., brain and spinal cord) are
treatable with steroids and radiation in the ambulatory setting,
but changes in mental status and the development of seizures
may require ICU care.
As a general rule, oncologists have become increas-
ingly sophisticated in managing these problems as outpatient
events but not necessarily more adept at recognizing when
such an approach is about to take a dramatic turn for the
worse; consequently, patients who arrive at the medical ICU
are often in a rapidly deteriorating situation.
Treatment-Related Complications
Treatment for lung cancer varies from curative surgical
interventions to efforts at palliation of symptoms; all of them
cause varying degrees of complications, some of which can
result in admission to the medical ICU.
When patients are not carefully assessed preopera-
tively, their resulting loss of pulmonary volume, coupled with
the effects of anesthesia, may lead to acute respiratory de-
compensation that goes beyond normal postoperative care
and requires medical ICU admission. Patients who have had
a pneumonectomy may develop postoperative acute respira-
tory distress syndrome in the remaining lung, and patients
who have had decompression of a large pericardial effusion
may develop acute cardiac decompensation.8
Radiation damage to the lung is generally characterized
by an acute inflammatory phase, with symptoms consisting of
a nonproductive cough, followed by a slower stage of fibrosis
and scarring that takes, on average, 3 to 9 months to fully
manifest itself. Occasionally, the resulting loss of pulmonary
capacity in the fibrotic stage will cause respiratory decom-
pensation. Uncommonly, radiation pneumonitis can be a
florid inflammatory process and occur outside of the radiation
portals as well as within. This diagnosis requires rapid initi-
ation of high-dose steroids, but even that may not be suffi-
cient and these patients may need significant ventilatory
support. Pathologically, this is manifested by diffuse lung
injury consistent with acute respiratory distress syndrome.9 In
most instances, particularly with the later generation chemo-
therapeutic compounds such as paclitaxel, docetaxel, gemcit-
abine, and navelbine, the inflammatory response to radiation
is greatly increased.
Several chemotherapeutic agents—including gemcitab-
ine, gefitinib or erlotinib, etoposide, paclitaxel, docetaxel,
mitomycin, methotrexate, and bevacizumab—are associated
with pulmonary toxicity and acute respiratory failure.
Uniquely, bevacizumab can cause central necrosis in lung
cancers with concomitant erosion of the pulmonary vascula-
ture and a catastrophic episode of massive hemoptysis. High-
dose chemotherapy, as is used for acute leukemia and stem
cell transplantation, can cause significant immune suppres-
sion with the development of unusual viral and fungal infec-
tions. The more traditional doses used in the common solid
tumors rarely cause significant immune suppression but do
cause suppression of the inflammatory response and profound
neutropenia, which can lead to serious episodes of bacterial
infection and sepsis. In general, oncologists are adept at
recognizing and treating these complications on a routine
basis, so that the only cases that make it to the medical ICU
are those with severe sepsis and septic shock. The differen-
tiation between infectious and treatment-related pulmonary
complications may be challenging.
Comorbid Illnesses
The risk of contracting a variety of respiratory or
cardiovascular problems is increased in lung cancer patients
according to age and cigarette smoking. Patients may need
medical ICU care for acute exacerbation of chronic obstruc-
tive pulmonary disease, cardiogenic pulmonary edema, acute
coronary syndrome, or other illness such as acute renal
failure. The indication for medical ICU may be due to a
combination of the above conditions.
TABLE 1. Main Indications for Medical ICU Admission
Cancer-related complications
● Superior vena cava (SVC) obstruction








● Chemotherapy induced pulmonary toxicity
● Bronchoscopic or other procedural complications
● Post cancer resection
Infections
● Directly related to the cancer, e.g., obstructive pneumonia
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MEDICAL ICU OUTCOME OF LUNG
CANCER PATIENTS
In general, early studies suggested that the ICU out-
come of cancer patients is poor.10–14 Studies that specifically
evaluated lung cancer patients also reported that the medical
ICU outcome of these patients was poor (Table 2).15 In a
report by Ewer et al.,16 the hospital mortality rate of 46
mechanically ventilated lung cancer patients was 91%. In
2000, Boussat et al.17 reported overall ICU mortality of 66%
and 71% for those requiring mechanical ventilation. The
hospital mortality in that cohort was 75%. Lin et al.18 ana-
lyzed the outcome of 81 mechanical ventilated lung cancer
patients admitted from 1995 to 1999 and reported a hospital
mortality of 85%. These earlier studies cast doubt about the
utility of ICU care in patients with lung cancer and suggest
that such patients should not be subjected to intensive care if
they develop critical illnesses.
On the other hand, more recent literature reports that the
outcome of lung cancer patients admitted to the medical ICU has
been steadily improving. In 2006, Reichner et al.19 reported
overall ICU mortality of 43%, and 74% for those requiring
mechanical ventilation. Another study by Soares et al.20 in 2007
reported ICU mortality of 42% and 69% for those receiving
mechanical ventilation. More recently, Adam and Soubani7
reported the outcome of 139 lung cancer patients, including
68 mechanically ventilated patients, who were admitted to the
medical ICU. Sixty-eight percent of the patients were African
Americans, and 66% of the patients had extensive disease.
The overall ICU mortality was 22% and 38% for those who
were on mechanical ventilation. The hospital mortality for the
whole group was 40%, and 52% of the patients who were
discharged from the hospital were still alive more than 6
months later. Other studies have shown—in addition to an
improved survival rate of lung cancer patients admitted to the
ICU—an increased availability of cancer therapy for the
survivors, causing a higher long-term survival rate. A study
by Roques et al. evaluated the long-term outcome of 141 lung
cancer patients admitted to the ICU. The ICU and hospital
mortality rates were 43% and 54%, respectively. Sixty-eight
percent of the survivors received treatment for the underlying
cancer with 6 months survival of 79% versus 21% for those
who did not receive cancer therapy.21 These data show that
there is a clear trend toward improved overall survival of lung
cancer patients admitted to the medical ICU, and although
those who are mechanically ventilated had a higher mortality
rate, still, the survival rate for this subgroup has improved.
Another observation is that the ICU outcome of lung cancer
patients is generally approaching that of other patient popu-
lations admitted to the medical ICU. In a subgroup analysis of
the Sepsis Occurrence in Acutely Ill Patients Study, there
were 473 patients with cancer, and lung cancer was one of the
commonest malignancies. The hospital mortality rate in pa-
tients with solid malignancies was 27%, which was not
significantly different from critically ill patients without can-
cer (23%).22
It is difficult to establish the specific reasons for the
improved ICU outcome of lung cancer patients; however,
factors that have been shown to improve ICU outcome in
other patient populations are likely to apply to these patients
as well. These factors may be related to improved mechanical
ventilation strategies that minimize further lung injury and
increased use of noninvasive ventilation. Studies report that
the early use of noninvasive ventilation in cancer patients
have resulted in improved gas exchange, decreased dyspnea,
less mechanical ventilation, and lower overall mortality
rates.23,24 In one study, 48 cancer patients who were managed
with noninvasive ventilation were matched to another group
of patients who were mechanically ventilated. The crude
30-day mortality of the noninvasive ventilation group was
43.7% compared with 70.8% for the mechanically ventilated
patients.23 Other factors—better management of sepsis and
implementation of patient safety bundles of care (such as the
ventilator bundle and sepsis bundle)—may play a role in
better ICU outcome. Furthermore, the multidisciplinary ap-
proach to the management of these patients with the involve-
ment of intensivists, oncologists, and other specialists con-
tributes to the better management of critically ill lung cancer
patients. The improvement in the different therapeutic op-
tions for lung cancer and the increased knowledge and expe-
rience developing in units that routinely deal with cancer
patients will contribute to improved outcome of these pa-
tients. However, the fact that most of the reported literature













Ewer et al.16 46 100 85 91 98
Boussat et al.17 57 91 67 75 NR
Lin et al.18 81 100 73 85 NR
Reichner et al.19 47 49 43 60 NR
Soares et al.20 143 70 42 59 67
Mendoza et al.15 34 63 NR 43 NR
Adam et al.7 139 49 22 40 69
Roques et al.21 105 41 43 54 73
Toffart et al.25 103 40 31 48 63
a Long-term survival signifies survival 6 mo (except for Toffart et al., 3 mo) after medical ICU admission.
ICU, intensive care unit; NR, not reported.
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about ICU outcome of lung cancer patients comes from
specialized units that routinely deal with cancer patients may
be a source for bias in the reported improved outcome of
critically ill lung cancer patients. Prospective, multicenter
trials are needed to confirm these results. Furthermore, the
long-term outcomes of those patients who survive ICU care,
including their quality of life and the cost of this care, are not
known and need more rigorous analysis.
PREDICTORS OF MEDICAL ICU OUTCOME OF
LUNG CANCER PATIENTS
Despite the improved ICU and hospital outcome of
lung cancer patients reported in the recent literature, not all
patients benefit from this aggressive care. For many patients
with lung cancer, ICU care is futile and will not prolong their
lives. Such therapy may be associated with a huge emotional
and physical toll on these patients and their families. In
addition, such care is very expensive and will consume scarce
resources. It would be useful to be able to predict, before
admission to the ICU, whether the patient is going to benefit
from this aggressive and expensive therapy.
Several retrospective studies tried to identify the clini-
cal variables that are associated with poor ICU outcome
(Table 3). In a study by Soares et al.,20 the predictors of poor
ICU outcome were severity of comorbid illnesses, number of
organ system failures, cancer recurrence or progression, and
airway infiltration or obstruction by cancer. Some of the
predictors that were reported in the study by Reichner et al.19
were the need for mechanical ventilation, advanced lung
cancer stage, and higher Sepsis-related or Sequential Organ
Failure Assessment score. The death predictive factors in the
study by Boussat et al.17 were acute pulmonary disease and
Karnofsky performance status less than 70. In the study by
Adam and Soubani,7 several predictors correlated with poor
ICU outcome. These included high admission Acute Physi-
ology and Chronic Health Evaluation III score, the need for
mechanical ventilation, the use of vasopressors, positive
blood cultures, high serum lactate, the presence of two or
more organ system failures, and the need for Advanced
Cardiac Life Support (ACLS) protocol for cardiopulmonary
arrest. On multiregression analysis, only the use of vasopres-
sors and the presence of two or more organ system failures
predicted poor ICU outcome, with odds ratio (OR) 8.7 and
40.8, respectively. The stage of lung cancer or the presence of
metastasis did not correlate with poor medical ICU outcome.
This was similar to the findings in the study by Boussat et al.17
but in contrast to the findings of Soares et al.20 and
Reichner et al.19 Regarding the type of lung cancer, the
studies have shown variable results. A recent study observed
that patients with non-small cell lung cancer had a favorable
ICU outcome,7 which is in contrary to the findings of other
studies.17,19 Another study by Roques et al. reported that the
predictors of hospital mortality for lung cancer patients ad-
mitted to the ICU were performance status 2 (OR 3.6, 95%
confidence interval [CI] 1.5–8.7) and acute respiratory failure
(OR 3.5, 95% CI 1.5–8.4), whereas the predictors for long-
term survival (6 month) were cancer progression (hazard ratio
[HR] 6.1, 95% CI 2.2–17) and the need for mechanical
ventilation (HR 3.6, 95% CI 1.35–9.4).21 A recent study of
103 lung cancer patients admitted to the ICU reported that the
predictors of 3-month outcome were performance status more
than 2 (HR 2.65; 95% CI 1.43–4.88), metastasis at admission
(HR 1.90; 95% CI 1.08–3.33) and worse Logistic Organ
Dysfunction (LOD) score (HR 1.19; 95% CI 1.08–1.32).
Furthermore, the study suggests that assessment of the LOD
score after 72 hours of admission to the ICU was useful in
predicting the outcome of these patients. Mortality was 8%
when the LOD score improved, compared with 29% when the
score did not change and 45% when the score worsened.25
It is difficult to come out with absolute predictors of
outcome of lung cancer patients admitted to the ICU because
of studying different predictors, different analysis methods,
and different final outcomes (ICU versus hospital versus long
term). However, these studies suggest that the need for
mechanical ventilation, poor baseline performance status, and
lung cancer refractory to therapy are more likely to be
associated with poor ICU and hospital outcomes. On the other
hand, these studies suggest that age and type and stage of lung
cancer were not predictors of outcome and probably should not
be criteria by themselves against ICU care. Also, the studies
suggest that the different acuity scores (such as Acute Physiol-
ogy and Chronic Health Evaluation III and Sepsis-related or
Sequential Organ Failure Assessment) used to assess the out-
come of critically ill patients did not uniformly predict the
outcome of these patients. This observation has also been re-
ported with critically ill cancer patients in general.27
Given the difficulty in determining the futility of ICU
care for patients with lung cancer on initial evaluation of their
critical illness, it is reasonable to offer this care to all
critically ill lung cancer patients except those who have
advanced malignancy unresponsive to therapy or have made
a decision against aggressive therapy. Treatment of these
patients who are admitted to the medical ICU should include
appropriate diagnostic studies, ventilator support (either by
noninvasive positive pressure ventilation or mechanical ven-
tilation), hemodynamic support, and, when necessary, renal
replacement therapy. These patients should be reevaluated in
3 to 5 days to assess their response to therapy.25,28–30 If they
are not responding to therapy, continue to require full me-
chanical ventilation, or develop multiorgan system failure,
the patients and/or their families should be approached re-
garding limiting aggressive therapy and considering palliative
TABLE 3. Predictors of Medical ICU Outcome of Lung
Cancer Patients
Predictors Reference Numbers
Mechanical ventilation 7, 16, 18, 19, 21
Severity of comorbid illnesses 20
Number of organ system failure 7, 20, 25
Cancer recurrence or progression 15, 19, 20, 21, 25
SOFA score 19
Logistic Organ Dysfunction (LOD) score 25
Performance status 17, 21, 25
Hemodynamic instability requiring vasopressors 7
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care. Such discussions should include the intensivist, medical
oncologist, and preferably palliative care consultant.
Although aggressive therapy is appropriate in patients
with lung cancer, it seems that performing ACLS protocol on
those with critical illness is futile. Studies have shown that it
is unusual for critically ill cancer patients who suffer cardiac
arrest and undergo ACLS protocol to survive their hospital-
ization.5,10,31 In a study of 244 cancer patients (46% with
solid tumors) who had in-hospital cardiac arrest, only 16
patients (7%) were discharged alive. In 70% of the study
patients, the cardiac arrest developed in those who had
gradual progression toward arrest after sepsis, unresponsive
cardiogenic shock, acidosis, or multiple organ dysfunction
syndromes. In this group of patients, which is typical of
patients treated in the ICU, none of the patients was dis-
charged alive from the hospital.26 These observations may be
conveyed to patients and their family members to avoid
subjecting the patients to ACLS protocol if their conditions
deteriorate.
An important aspect in the care of the lung cancer
patient should be an early discussion about the extent of
treatment the patient wishes and end-of-life issues. From
experience, and documentation in literature, it can be said that
the majority of lung cancer patients admitted to the medical
ICU did not have discussions with their oncologists about the
extent of treatment they wish to receive nor have they
addressed their code status. This adds an extra burden, and
sometime confusion, among physicians and family members
about the patient’s wishes. Critically ill lung cancer patients
may not be able to make informed decisions and their
families may not know the patients’ preferences. Thoughtful
decisions about end-of-life issues are difficult under these
stressful situations. In a study by Reichner et al., only 26% of
lung cancer patients admitted to the medical ICU had Do-
Not-Resuscitate orders, and 64% of patients with stage IV
non-small cell lung cancer were full code. In those patients
who were full code on admission to the medical ICU, there
were no records of end-of-life discussions documented in any
of the available outpatient records. The code status was
subsequently changed to Do-Not-Resuscitate in 49% of the
patients a mean of 7 days after admission to the medical ICU.
The pulmonary and critical care physician was solely respon-
sible for the change in the code status in 65% of the cases.19
Another study by Lamont et al.32 showed that physicians
provide frank estimate of prognosis in only one-third of cases
and in the rest provide no estimate or consciously overesti-
mate or underestimate survival time. It may be understand-
able for the oncologists not to discuss end-of-life care as they
are starting treatment for these patients; however, they are in
the best position to have frank discussions with their patients
and family members, in the outpatient setting, after they had
a good rapport with them and had a time to assess the
patients’ health and response to therapy. An important re-
source to physicians caring for lung cancer patients is con-
sultation with palliative care services that support the patient,
family, and physicians as they are going through treatment
and in making end-of-life decisions. Recent observations
have shown that such services are underused especially in
critically ill patients. A study of cohort of patients with newly
diagnosed metastatic non-small cell lung cancer was random-
ized to receive either early palliative care integrated with
standard oncologic care or standard oncologic care alone.
Their quality of life and mood were assessed at 12 weeks.
The patients assigned to early palliative care had better
quality of life—as measured by the Functional Assessment of
Cancer Therapy-Lung scale—than did patients assigned to
standard care. In addition, fewer patients in the palliative care
group than in the standard care group had depressive symp-
toms (16% versus 38%, p 0.01). Fewer patients in the early
palliative care group than in the standard care group received
aggressive end-of-life care—defined as chemotherapy within
14 days before death, no hospice care, or admission to
hospice 3 days or less before death (33% versus 54%, p 
0.05). However, the median survival was longer among
FIGURE 1. A suggested approach to the man-
agement of critically ill lung cancer patients. NIV,
noninvasive ventilation; MV, mechanical ventila-
tion; RRT, renal replacement therapy.
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patients receiving early palliative care (11.6 months versus
8.9 months, p  0.02).33 Furthermore, making use of the
palliative care services has been associated with lowered cost
for care of cancer patients.34 The recent American College of
Chest Physicians guidelines for the diagnosis and manage-
ment of lung cancer recommend that palliative care, includ-
ing a consultation with a palliative care team, be integrated
into the treatment of patients with advanced lung cancer, even
for those pursuing curative or life-prolonging therapies.35
CONCLUSION
Lung cancer patients commonly develop critical ill-
nesses that require admission to the medical ICU. The sever-
ity of the acute illness, the number of organ system failures,
and the patient’s pre-event performance status seem to be
important factors in predicting the outcome of these critically
ill patients. Full ICU support should be considered for all
lung cancer patients who wish to have it or whose wishes are
not known; the exceptions to this care are patients who
clearly have an advanced refractory disease or poor perfor-
mance status. The best form of management for such patients
is a multidisciplinary team approach that includes the inten-
sivist, medical oncologist, and palliative care specialist. This
team should reassess the patient’s condition in the ICU and
communicate frequently with the patient and/or family to
provide the most appropriate care for the patient (Figure
1). Every effort should be made to discuss the patient’s end
of life decisions and code status by their medical oncolo-
gist in the outpatient setting. Although lung cancer patients
admitted to the medical ICU have often posed a significant
mortality rate, their outcome has been progressively im-
proving and is approximating that of the general critically
ill population.
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